
STROKE
NCD
TBI
SMALL MOMENT.
BIG DIFFERENCE.
Susan is suffering from cognitive impairment.
Today, she's making her next big move.
Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.

…THE SOONER THE BETTER?

Early intervention with Cerebrolysin®. **A very promising concept.**[1]

Focus:
Mild cognitive impairment



Very early intervention

with Cerebrolysin® ** (Group 2):

80 % **Marked & moderate** cognitive improvement in 80 % of patients (CGI scale)

55 % **Marked** cognitive improvement in 55 % of patients (CGI scale)

* confirmed by objective clinical and neuropsychological examination
** relatives of AD patients with no subjective cognitive difficulties#
# their anamnesis revealed abnormal cognitive development and signs of constitutional cognitive insufficiency

Cerebrolysin®

EXPERIENCING SUCCESS.

Small moment. BIG difference.

REMARKABLE COGNITIVE IMPROVEMENT

with Cerebrolysin® *,[2]

Focus:
Mild cognitive impairment

Cerebrolysin®:

+ 141%

more cognitive improvement vs. placebo* (ADAS-cog+) [2]

P < 0,0001

"Dementia is a major global health problem … there is increasing focus on risk reduction, **timely diagnosis** and **early intervention**"

Review > BMJ. 2015, Louise Robinson et al., Dementia: timely diagnosis and early intervention.

* ADAS-cog+ least squares (LS) mean change from baseline was -10,6 points in the Cerebrolysin® group vs. -4,4 points in the placebo group (after 24 weeks of treatment, n = 242, P < 0,0001 vs. placebo)

Cerebrolysin®

INCREASE THE LEVEL OF ACTIVITIES

with Cerebrolysin® [2]

Focus:
Mild cognitive impairment



ADCS-ADL Score:

- **Constant improvements** in Cerebrolysin® group.

  Unchanged situation in placebo group.

- Even within the **follow-up-period consistent enhancements** in Cerebrolysin® group

Cerebrolysin®
Placebo

Cerebrolysin®

MULTIPLYING THE TARGET.

MULTITARGET

neurotrophic mode of action of Cerebrolysin®[3]

Focus:
Mild cognitive impairment

Cerebrolysin® Neuropeptides

Multi-Target Activity

Neurotrophic-like Multimodal MoA

NEUROPLASTICITY ↗

NEUROREPAIR AD Mechanisms ↗

NEUROPREVENTION AD Pathology ↗

NEURORECOVERY Brain Functions

Cerebrolysin® → increases BDNF[4]

BDNF, one of the most important multimodal parameters, triggers multimodal MoA



Effect of Cerebrolysin® on BDNF serum levels (descriptive) in AD Patients at the end of the active Cerebrolysin® treatment period (16 weeks)[4]

Cerebrolysin®

ONE THERAPY FOR ALL NCDs[5]

All areas of neurocognitive disorders (NCDs) show similar symptoms, therefore it is difficult to diagnose, especially at an early stage.

- Mild cognitive impairment (MCI)
- Alzheimer's Disease (AD)
- Vascular Dementia (VD)
- Mixed Dementia
- Frontotemporal Dementia (FTD)

Cerebrolysin® - The therapy for ALL neurocognitive disorders

Cerebrolysin®

ADMINISTRATION OF CEREBROLYSIN®

Disorder	Daily dosage	Initiation of treatment	Treatment duration
Vascular dementia	10 – 30 ml	as soon as possible	**2 – 4 cycles / year** **1 cycle = 5 days weekly / 4 weeks**
Alzheimer's disease	10 – 30 ml	as soon as possible	**2 – 4 cycles / year** **1 cycle = 5 days weekly / 4 weeks**

Route of administration

- IV injection for 3 min: Up to 10 ml undiluted
- IV injection for 15 – 60 min: 10 ml – 50 ml diluted to at least 100 ml total volume with saline, Ringer solution for 5 % glucose solution
- 5 ml dosage (undiluted) can be administered intramuscularly

1) Selezneva N D et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(10):30-36. **2)** Guekht Alla B et al. J Stroke Cerebrovasc Dis. Jul-Aug 2011;20(4):310-8. **3)** Gavrilova SI, Alvarez A. Med Res Rev. 2021 Sep;41(5):2775-2803. **4)** Alvarez X A et al. Int J Neuropsychopharmacol. 2016 Jun;19(6):1-6. **5)** Thome J. Cerebrolysin®: a review of a neurotrophic treatment strategy in acute and chronic neurological disorders preface. Drugs of today 48 (2012): 1-63.

ABBREVIATED PRESCRIBING INFORMATION - Cerebrolysin®. name of the medicinal product: Cerebrolysin® - Solution for injection. Qualitative and quantitative composition: one ml contains 215.2 mg of Cerebrolysin® concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: for treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.
CERE/INT/04/2022/4

EVER PHARMA

EVER Neuro Pharma GmbH

Oberburgau 3 | 4866 Unterach | Austria
www.everpharma.com | www.cerebrolysin.com